Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

GDF15(MIC1) H6D Polymorphism Does Not Influence Cardiovascular Disease in a Latin American Population with Rheumatoid Arthritis.

Amaya-Amaya J, Rojas-Villarraga A, Molano-Gonzalez N, Montoya-Sánchez L, Nath SK, Anaya JM.

J Immunol Res. 2015;2015:270763. doi: 10.1155/2015/270763. Epub 2015 May 18.

2.

Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review.

Amaya-Amaya J, Sarmiento-Monroy JC, Caro-Moreno J, Molano-González N, Mantilla RD, Rojas-Villarraga A, Anaya JM.

Autoimmune Dis. 2013;2013:794383. doi: 10.1155/2013/794383. Epub 2013 Nov 3.

3.

Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care - a retrospective database study.

Jameson K, Amber V, D'Oca K, Mills D, Giles A, Ambegaonkar B.

Int J Clin Pract. 2013 Dec;67(12):1228-37. doi: 10.1111/ijcp.12238. Epub 2013 Aug 14.

4.

Cardiovascular risk scores: qualitative study of how primary care practitioners understand and use them.

Liew SM, Blacklock C, Hislop J, Glasziou P, Mant D.

Br J Gen Pract. 2013 Jun;63(611):e401-7. doi: 10.3399/bjgp13X668195.

5.

Usefulness of patients-reported outcomes in rheumatoid arthritis focus group.

Amaya-Amaya J, Botello-Corzo D, Calixto OJ, Calderón-Rojas R, Domínguez AM, Cruz-Tapias P, Montoya-Ortiz G, Mantilla RD, Anaya JM, Rojas-Villarraga A.

Arthritis. 2012;2012:935187. doi: 10.1155/2012/935187. Epub 2012 Sep 28.

6.

Perceptions of risk: understanding cardiovascular disease.

Webster R, Heeley E.

Risk Manag Healthc Policy. 2010;3:49-60. doi: 10.2147/RMHP.S8288. Epub 2010 Sep 6.

7.

Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study.

Ting RZ, Yang X, Yu LW, Luk AO, Kong AP, Tong PC, So WY, Chan JC, Ma RC.

Cardiovasc Diabetol. 2010 Nov 22;9:77. doi: 10.1186/1475-2840-9-77.

8.

Context and cardiovascular risk modification in two regions of Ontario, Canada: a photo elicitation study.

Angus JE, Rukholm E, Michel I, Larocque S, Seto L, Lapum J, Timmermans K, Chevrier-Lamoureux R, Nolan RP.

Int J Environ Res Public Health. 2009 Sep;6(9):2481-99. doi: 10.3390/ijerph6092481. Epub 2009 Sep 17.

9.

The independent relationship between triglycerides and coronary heart disease.

Morrison A, Hokanson JE.

Vasc Health Risk Manag. 2009;5(1):89-95. Epub 2009 Apr 8. Review.

10.
11.

Cessation of hormone replacement therapy after reports of adverse findings from randomized controlled trials: evidence from a British Birth Cohort.

Mishra G, Kok H, Ecob R, Cooper R, Hardy R, Kuh D.

Am J Public Health. 2006 Jul;96(7):1219-25. Epub 2006 May 30.

12.
14.

Decision tools in health care: focus on the problem, not the solution.

Liu J, Wyatt JC, Altman DG.

BMC Med Inform Decis Mak. 2006 Jan 20;6:4.

16.

Aspirin for everyone older than 50? For.

Elwood P, Morgan G, Brown G, Pickering J.

BMJ. 2005 Jun 18;330(7505):1440-1. Review. No abstract available.

17.
18.
19.
20.

Targeting the renin-angiotensin system in patients with renal disease.

Devonald MA, Karet FE.

J R Soc Med. 2002 Aug;95(8):391-7. Review. No abstract available.

Supplemental Content

Support Center